{"id":4769,"date":"2021-12-15T21:11:37","date_gmt":"2021-12-16T02:11:37","guid":{"rendered":"https:\/\/www.wmfc.ca\/?p=4769"},"modified":"2022-02-02T16:56:00","modified_gmt":"2022-02-02T21:56:00","slug":"journal-article-btk-inhibitors-for-the-treatment-of-wm-a-canadian-perspective","status":"publish","type":"post","link":"https:\/\/www.wmfc.ca\/fr\/2021\/12\/15\/journal-article-btk-inhibitors-for-the-treatment-of-wm-a-canadian-perspective\/","title":{"rendered":"Article de journal : Inhibiteurs de BTK pour le traitement de la MW : une perspective canadienne"},"content":{"rendered":"<p>Cet article du Dr Fr\u00e9d\u00e9ric Larose et de notre collaboratrice habituelle, le Dr Christine Chen, compare divers inhibiteurs de la BTK et fournit \u00e9galement une comparaison et une justification de l'utilisation continue de la Bendamustine + Rituximab dans le contexte canadien.  Aucun nouveau r\u00e9sultat de recherche n'est pr\u00e9sent\u00e9 ; l'article est un r\u00e9sum\u00e9 des connaissances existantes, et peut donc \u00eatre utile \u00e0 ceux qui cherchent \u00e0 rafra\u00eechir leurs connaissances sur ces m\u00e9dicaments et leur histoire, ainsi que sur la place de ces m\u00e9dicaments dans le syst\u00e8me de sant\u00e9 canadien.  .<\/p>\n<p>Les sections comprennent :<\/p>\n<ul>\n<li>Le paysage actuel des traitements au Canada (tr\u00e8s lisible pour le profane).<\/li>\n<li>Justification mol\u00e9culaire du ciblage de la tyrosine kinase de Bruton dans la MW (le dernier paragraphe est probablement le plus utile pour le profane).<\/li>\n<li>Donn\u00e9es cliniques \u00e9tayant l'utilisation des inhibiteurs de tyrosine kinase de Bruton dans la MW (souvent techniques ; avec des sous-sections couvrant l'Ibrutinib, le Zanubrutinib, l'Acalabrutinib, le Tirabrutinib, et les inhibiteurs non covalents de BTK, notamment le Pirtobrutinib (alias LOXO-305) et le MK-1026 (alias AQR-531))<\/li>\n<li>Conclusion - Quelle est la place des inhibiteurs de tyrosine kinase de Bruton dans le paysage th\u00e9rapeutique canadien (r\u00e9sum\u00e9 utile, lecture recommand\u00e9e).<\/li>\n<\/ul>\n<p>Le texte int\u00e9gral de l'article est disponible \u00e0 l'adresse suivante <a href=\"https:\/\/touchoncology.com\/haematological-malignancies\/journal-articles\/brutons-tyrosine-kinase-inhibitors-for-the-treatment-of-waldenstroms-macroglobulinaemia-a-canadian-perspective\/\" target=\"_blank\" rel=\"noopener\">https:\/\/touchoncology.com\/haematological-malignancies\/journal-articles\/brutons-tyrosine-kinase-inhibitors-for-the-treatment-of-waldenstroms-macroglobulinaemia-a-canadian-perspective\/<\/a>.<\/p>\n<p>&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>This journal article by Dr. Frederic Larose and our frequent contributor Dr. Christine Chen compares various BTK inhibitors, and also provides comparison with and rationale for the continued use of Bendamustine + Rituximab in the Canadian context.\u00a0 No new research results are presented; the article is a summary of existing knowledge, and thus can be useful to those looking to refresh their knowledge about these drugs and their histories, and the place of the drugs in the Canadian healthcare system.\u00a0 . Sections include: Current treatment landscape in Canada (very readable to the lay person) Molecular rationale for targeting Bruton\u2019s tyrosine kinase <a href=\"https:\/\/www.wmfc.ca\/fr\/2021\/12\/15\/journal-article-btk-inhibitors-for-the-treatment-of-wm-a-canadian-perspective\/\"> [&#8230;]<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_price":"","_stock":"","_tribe_ticket_header":"","_tribe_default_ticket_provider":"","_ticket_start_date":"","_ticket_end_date":"","_tribe_ticket_show_description":"","_tribe_ticket_show_not_going":false,"_tribe_ticket_use_global_stock":"","_tribe_ticket_global_stock_level":"","_global_stock_mode":"","_global_stock_cap":"","_tribe_rsvp_for_event":"","_tribe_ticket_going_count":"","_tribe_ticket_not_going_count":"","_tribe_tickets_list":"[]","_tribe_ticket_has_attendee_info_fields":false,"footnotes":""},"categories":[20],"tags":[],"class_list":["post-4769","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts\/4769","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/comments?post=4769"}],"version-history":[{"count":6,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts\/4769\/revisions"}],"predecessor-version":[{"id":4776,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/posts\/4769\/revisions\/4776"}],"wp:attachment":[{"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/media?parent=4769"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/categories?post=4769"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.wmfc.ca\/fr\/wp-json\/wp\/v2\/tags?post=4769"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}